Recent Activity in the Marketplace


  • WuXi AppTec Will Acquire ResearchPoint Global

    October 19, 2017 — WuXi AppTec, China’s largest CRO/CMO, will acquire clinical-stage contract research company, ResearchPoint Global, of Austin, Texas. Founded in 1999, RPG has 450 employees in 60 countries. The company offers a range of clinical CRO services to small and medium-sized pharmas. Financial details were not disclosed.

  • Quest Diagnostics Inc. Acquires Cleveland HeartLab

    October 18, 2017 — Quest Diagnostics Inc. announced it will acquire Cleveland HeartLab, a purveyor of diagnostic services for managing cardiovascular disease, from equity investors. Quest intends to establish a national center of excellence in diagnostic information services at Cleveland HeartLab’s specialized laboratory in Cleveland, Ohio, focused on services that aid in assessing risk and treatment protocols for heart disease.

  • Brooks Automation Buys 4titude, Ltd. for $65M

    October 05, 2017 — Brooks Automation, Inc. has acquired 4titude, Ltd., a manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications. Based in Surrey, England, 4titude provides consumable PCR plates which are used to amplify small segments of DNA, as well as a range of sealing and sequencing tubes related to bench top instrumentation. They have over 1200 global customers in the pharma, biotech, academic, and biobanking markets.

  • Precision For Medicine Acquires Epiontis

    October 4, 2017 — Precision for Medicine, part of the Precision Medicine Group, has acquired Berlin-based Epiontis GmbH, a next-generation European specialty laboratory providing immune monitoring services through an epigenetic platform. The acquisition adds Epiontis’s epigenetic technology and expertise to Precision’s suite of immune monitoring services for clinical trials.

  • Bruker Acquires Merlin Diagnostika GmbH

    September 26, 2017 — Bruker announced the acquisition of Merlin Diagnostika GmbH, located near Bonn, Germany. Merlin provides products, services and consulting in the fields of antibiotic resistance testing and antibiotic susceptibility testing. MERLIN’s technology and product portfolio for human and veterinary antibiotic resistance and specialty susceptibility testing will enable Bruker to add these tests to its MALDI Biotyper® Microbial Identification Platform. Merlin will become Bruker´s Center of Excellence for specialty biochemical and selected, high-value MALDI Biotyper-based antibiotic resistance and susceptibility testing.

  • Thermo Fisher Scientific Buys Patheon for $7.2B

    May 15, 2017 — Thermo Fisher Scientific has purchased North Carolina-based Patheon N.V. in a deal worth $7.2 billion, which includes the assumption of $2 billion in debt.  Patheon is a provider of manufacturing outsourcing services and outsourced pharmaceutical development services.  They had revenues of about $1.6 billion in 2016, and will become part of Thermo Fisher’s Laboratory Products and Services Segment.

  • MilliporeSigma Acquires Grzybowski Scientific Inventions

    May 9, 2017 — MilliporeSigma has acquired Grzybowski Scientific Inventions for an undisclosed amount.   Grzybowski has developed a computer-aided retro-synthesis tool, Chematica, which quickly provides optimized routes, aiding researchers in medicinal chemistry and drug discovery.

  • Bruker Acquires Microscopy Company Luxendo

    May 8, 2017 — Bruker has acquired Luxendo, a privately held spin-off of the European Molecular Biology Laboratory, which produces proprietary light-sheet fluorescence microscopy instruments.  Luxendo’s single plane illumination microscopy technique reduces sampling times over conventional laser scanning confocal microscopes, while reducing damaging side effects on living specimens.

  • Avantor will acquire VWR for $6.4B

    May 5, 2017  – Avantor, a global supplier of ultra-high-purity materials for the life sciences and advanced technology industries will acquire VWR, a major provider of product, supply chain, and service solutions to laboratory and production customers.

  • NantOmics Acquires Genos

    April 13, 2017 — NantOmics, a provider of molecular diagnostics services, has acquired Genos, a crowdsourcing platform for genomics research and discovery.  Genos was spun out of Complete Genomics in 2016.  NantOmics will integrate the Genos technology into its pan-omic analysis tools, supporting the company’s precision medicine service that integrates whole genomic sequencing, transcriptomics, predictive proteomics and quantitative proteomics.

  • VWR Acquires Reliable Biopharmaceutical and BioArra

    November 3, 2016 — VWR International, Inc. announced the acquisition of two companies, Reliable Biopharmaceutical and BioArra. Reliable Biopharmaceutical is a manufacturer of active pharmaceutical ingredients and high purity ingredients such as cGMP excipients and advanced intermediates for the biopharmaceutical industry. BioArra is a producer of U.S. origin serum-based products for use in research and production.

  • PierianDx Acquires Tute Genomics

    October 12, 2016 — PierianDx, a provider of clinical genomic analysis, interpretation and reporting acquired Tute Genomics, a genomics software company based in Provo, UT. PierianDx’s Clinical Genomicist Workspace, a cloud-based software platform for somatic cancer, will be enhanced through the addition of Tute Genomics’ exome testing capabilities.

  • Phenomenex Acquired by Danaher

    October 12, 2016 — Phenomenex Inc., purveyor of separation and purification technology for researchers in industrial, clinical research, governmental and academic laboratories, will be acquired by Danaher Corporation. Phenomenex will operate as a standalone operating company, retaining the Phenomenex brand, its personnel and site locations. Though details of the deal weren’t disclosed, analysts estimate that Danaher paid more than $700 million for the company.

  • Aptean Acquires GQ Life Sciences

    October 4, 2016 – Aptean, a leading enterprise software company, has entered the Life Sciences and Big Data markets with the acquisition GQ Life Sciences, a provider of life science patent search solutions. GQ Life Sciences’ main product, GenomeQuest, enables researchers to search for biological sequences across approximately 815,000 worldwide patents (or more than 345 million sequences). Terms of the deal were not disclosed.

  • Caprion Biosciences Acquires the Immune Monitoring Laboratory

    September 13, 2016 — Caprion Biosciences has acquired the assets of the immune monitoring laboratory of ImmuneHealth, ASBL. Located in Gosselies, Belgium, the ImmuneHealth laboratory will provide a fully operational immune monitoring laboratory infrastructure which Caprion will leverage to expand its immune monitoring offering. The ImmuneHealth lab also has expertise and assays for cellular and humoral immunity to further Caprion’s efforts in the areas of infectious diseases and vaccine development.

  • Bruker Corporation to Acquire Oncovision's Preclinical PET Imaging Business

    September 7, 2016 — Bruker will acquire the preclinical imaging business of Oncovision, a provider of medical imaging devices used for the diagnosis of cancer. Financial terms of the agreement were not disclosed. For the past five years, Bruker and Oncovision have partnered on marketing and product development.

  • Danaher Buys Cepheid for $4B

    September 6, 2016 — Danaher Corp. is buying California molecular diagnostics company Cepheid Inc. for about $4 billion in cash. Cepheid manufactures various diagnostics systems that can be used to manage infectious diseases and cancers, as well as genetic-based disorders. Cepheid’s GeneXpert System offers 23 tests outside the U.S., and 20 tests in the U.S. Cepheid will join Danaher’s diagnostic business, which has about $4.8 billion in annual sales.

  • LabCorp Acquires Sequenom for $302M

    July 27, 2016 — Laboratory Corporation of America Holdings (LabCorp) will acquire Sequenom in a cash offer for an equity value of $302 million, which represents a total enterprise value of approximately $371 million, including net indebtedness. Sequenom offers molecular genetic laboratory-developed tests providing early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.

  • Caprion Biosciences Acquired by GHO Capital

    July 20, 2016 — Caprion Biosciences has been recapitalized and acquired by GHO Capital, a healthcare investor based in London, UK. The company was acquired from Chicago Growth Partners, Caprion’s majority shareholder since 2012. Financial details of the transaction were not disclosed. Caprion is a provider of immunology and proteomics analytical laboratory services to pharmaceutical and biotechnology companies.

  • Bio-Techne Acquires Advanced Cell Diagnostics for $325M

    July 6, 2016 — Bio-Techne Corporation has agreed to acquire Advanced Cell Diagnostics for $250 million in cash plus contingent $75 million due upon the achievement of certain milestones. The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition. ACD develops and commercializes proprietary consumables for genomic analysis, including the widely used in-situ hybridization technique.

  • Sartorius Corporation Acquires IntelliCyt for $90

    June 28, 2016 — Sartorius, a pharmaceutical and laboratory equipment provider, acquired U.S. based IntelliCyt Corporation, provider of novel cell screening platforms used in drug discovery.  Sartorius purchased IntelliCyt for $90 million in cash, which includes approx. $5 million in future tax savings.

  • Agilent Technologies to Acquire iLab Solutions

    June 27, 2016 — Agilent will acquire iLab, a provider of cloud-based solutions for core laboratory management. The acquisition includes iLab’s technology, intellectual property and product portfolio, as well as employee talent. A privately held company based in Boston, Mass., iLab Solutions provides laboratory management services to leading universities, research hospitals and independent institute.

  • Charles River Laboratories Acquires Blue Stream Laboratories

    June 27, 2016 — Charles River Laboratories International, Inc. has acquired Blue Stream Laboratories, Inc. Blue Stream is an analytical contract research organization supporting the development of complex biologics and biosimilars. Located in Woburn, Massachusetts, the company has expertise in structural and functional protein characterization programs, and the development and validation of assays for current good manufacturing practice lot release and stability programs.

  • Oxford Immunotec to Acquire Imugen for $22.2M

    June 23, 2016 — Oxford Immunotec Global PLC a diagnostics company focused on proprietary tests for the management of immune-regulated conditions, will acquire Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction.

  • Integrated DNA Technologies Acquires ValueGene, Inc.

    June 10, 2016 — Integrated DNA Technologies, provider of custom nucleic acid synthesis, has acquired ValueGene, Inc., an oligonucleotide synthesis services company based in San Diego, California. ValueGene offers custom DNA and RNA oligonucleotide synthesis products, including PAGE and HPLC purification and modification services.

  • VWR International, Inc. Acquires JM Separations

    June 2, 2016 — VWR, a provider of laboratory products, services and solutions, has acquired JM Separations, B.V., a supplier of single-use fluid handling and separation technology products for pharmaceutical and biotech customers. JM Separations supplies complete single-use bag systems and custom solutions for media/buffer preparation, cell harvesting and for the clarification, concentration and chromatographic processes.

  • Myriad Acquires Sividon Diagnostics for $56M

    May 31, 2016 — Myriad Genetics has acquired the breast cancer prognostic test developer Sividon Diagnostics for ~ $56 million, including milestones. Sividon’s core EndoPredict product is a kit-based RNA expression test designed to assess the aggressiveness of breast cancer on a molecular level through the evaluation of 12 genes. EndoPredict will be added into Myriad’s existing oncology commercial channel with the goal of helping patients decide whether to safely forgo chemotherapy.

  • Thermo Fisher buys FEI for $4.2B

    May 27, 2016 — Thermo Fisher bought electron microscopy developer FEI Company for $4.2 billion, through the acquisition of stock at $107.5 per share in cash. FEI designs, manufactures and supports high-performance electron microscopy workflows that provide images and information at micro-, nano- and picometer scales. Based in Hillsboro, Oregon, FEI had 2015 revenues of $930 million, will become part of Thermo Fisher’s Analytical Instruments Segment.

  • Siemens Healthcare GmbH acquires NEO New Oncology AG

    May 17, 2016 — Siemens Healthineers has acquired NEO New Oncology AG, Cologne, Germany. The company’s cancer genome diagnostic platform NEO 1 will support pathologists and oncologists with comprehensive molecular information to help select targeted cancer therapies. NEO New Oncology is developing molecular profiling assays based on NGS, both for tissue specimens and body liquids.

  • Luminex buys Nanosphere for $58M

    May 16, 2016 — Luminex will acquire Nanosphere, a molecular microbiology and molecular diagnostic company, for approximately $58m. Luminex’s current infectious disease portfolio will benefit from Nanosphere’s Verigene technology, which is said to lead in the high-growth bloodstream infection segment.

  • Takara Bio to Acquire WaferGen for up to $50M

    May 13, 2016 — Takara Bio will acquire WaferGen Bio-systems for up to $50 million, under a merger agreement creating a combined company in genomics research. The deal will couple WaferGen’s ICELL8™ Single-Cell System, introduced late last year, with Takara Bio’s single-cell reagents for single-cell researchers worldwide. The combined company also plans to couple WaferGen’s Smart Chip PCR™ and Apollo 324™ platforms with Takara Bio’s global reagent product mix.

  • WuXi AppTec Acquires CRELUX GmbH

    April 15, 2016 – WuXi AppTec has acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich, Germany. The addition of Crelux complements existing capabilities within the WuXi structure-based drug discovery platform.

  • BUCHI Acquires Flash Chromatography From Grace

    April 12, 2016 – BÜCHI Labortechnik AG has acquired high performance REVELERIS Flash Chromatography Systems, GRACERESOLV, and ALLTECH ELSD 3300 product lines from W. R. Grace & Co. They will become part of BÜCHI’s chromatography portfolio and BÜCHI will provide service, support, and preventative maintenance services. Grace will continue to supply the purification media used in the REVELERIS product line.

  • LGC Buys Douglas Scientific

    April 6, 2016 – LGC has acquired the laboratory automation company Douglas Scientific from Kingdom Enterprises for an undisclosed price, expanding the LGC’s high-throughput PCR offerings. Douglas Scientific provides high-throughput PCR and quantitative PCR (qPCR) platforms, as well as consumables, to markets that include agbio and clinical research laboratories.

  • Pfizer Calls Off $160 Billion Allergan Deal

    April 6, 2016 – In case you missed it… Pfizer (PFE) announced that it is terminating its acquisition agreement with Dublin-based Allergan, citing the effects of the new U.S. Treasury regulations regarding tax inversions

  • QIAGEN N.V. Makes $100 Million Bid to Buy Exiqon A/S

    March 30, 2016 – QIAGEN N.V. has submitted a conditional voluntary takeover offer to the shareholders of Exiqon A/S to purchase all shares in Exiqon. The acquisition is expected to expand QIAGEN’s position in Sample to Insight solutions for RNA analysis. Exiqon is a leader in the emerging market for non-coding RNA (ncRNA) such as micro RNA (miRNA) and long non-coding RNA (lncRNA). Exiqon also brings to QIAGEN a portfolio of technologies and know-how used in molecular testing, including Locked Nucleic Acid (LNA) technology.

  • Gyros AB and Protein Technologies Merge

    March 16, 2016 – Gyros AB and Protein Technologies, Inc. have agreed to merge to form Gyros Protein Technologies AB . Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ knowledge in developing and manufacturing instruments for peptide synthesis. The Company will provide a range of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing.

  • LabCorp Acquires Assets of Pathology Inc.

    December 10, 2015 — Laboratory Corporation of America will acquire the assets of Pathology Inc., a women’s health laboratory that provides expertise in reproductive FDA donor testing, as well as anatomic, molecular, and digital pathology services. The terms of the deal were undisclosed.

  • IDT acquires AITbiotech Oligonucleotide Business

    December 1, 2015. — Integrated DNA Technologies Inc., a purveyor of custom nucleic acid synthesis, will acquire the oligonucleotide synthesis business of AITbiotech Pte. Ltd. of Singapore. AIT provides genomics services to research, healthcare, and biomedical industries in Singapore and Asia. The company’s MDx business focuses on infectious diseases, oncology genetic testing and pharmacogenetics.

  • Human Longevity Acquires Cypher Genomics

    November 30, 2015 — Human Longevity, Inc. has acquired Cypher Genomics, Inc., a genome informatics company offering human genomic interpretation software solutions. The San Diego-based company has 14 employees who will join HLI. Financial details of the deal were not disclosed.

  • Charles River Laboratories Acquires Oncotest GmbH

    November 18, 2015 — Charles River Laboratories International, Inc. has acquired Oncotest GmbH, a Freiburg, Germany-based contract research organization providing discovery services for oncology. Oncotest offers target discovery and validation services for preclinical oncology researchers. The company specializes in in vivo pharmacology services, using its patient-derived xenograft (PDX) tumor models, as well as in vitro assays using both commercially available and proprietary PDX-derived cell lines.

  • Abcam Acquiring AxioMx for $45M

    November 11, 2015 — Abcam plc to acquire AxioMx, Inc. for $20m upfront with further performance-based payments totalling $25m. These performance payments will be made over five years and are based upon successful completion of commercial and technical milestones. AxioMx, which was founded in 2012, has 28 employees and is based in Branford, Connecticut, U.S. It has developed a scalable in vitro recombinant monoclonal antibody technology which complements Abcam’s existing antibody and immunoassay capabilities.

  • Tute Genomics Acquires Knome

    November 2, 2015 — Tute Genomics, a provider of clinical sequencing informatics, acquired key assets of Knome, a human-genome interpretation company. Knome was co-founded in 2007 George Church.

  • Sigma-Aldrich Buys Duolink Portfolio from Olink

    October 29, 2015 — Sigma-Aldrich has acquired the Duolink product portfolio from Olink Bioscience for an undisclosed price. The acquisition includes intellectual property, sales, marketing and manufacturing assets. The Duolink product line is designed for researchers studying biological pathways and seeking improved sensitivity to uncover disease biomarkers. Duolink technology, based on PLA technology, is intended to enable researchers in visualizing low levels of proteins, protein modifications and individual protein interactions directly in fixed cells and tissue samples, without the need for overexpression.

  • Merck KGaA to Acquire Sigma-Aldrich for $17B

    September 22, 2015 — Merck KGaA will acquire Sigma-Aldrich for $17 billion, in a deal that will more than double the acquirer’s presence in life sciences tools and technologies by expanding the operations of the Merck Millipore tools subsidiary. The deal expands Merck Millipore by coupling its 60,000 products and solutions with the 230,000 chemicals, biochemicals, and other products Sigma-Aldrich manufactures and distributes to more than 1.4 million customers globally in research and applied labs, as well as in industrial and commercial markets. The combination will enable Merck Millipore to increase its presence in North America—and add a presence in Asia as R&D and manufacturing continue to expand worldwide.

  • MDx Health to acquire NovioGendix

    September 15, 2015 — MDx Health plans to acquire NovioGendix for up to $8.8 million. The deal expands MDx’s uro-oncology offerings with a non-invasive urine-based molecular biomarker test for prostate cancer. It is set to be launched to market next year in the U.S. and Europe. Privately-held NovioGendix has focused on developing the “liquid biopsy,” an mRNA-based test designed to help differentiate patients with aggressive, clinically significant prostate cancer, from those with slower growing cancer.

  • StoneCalibre Acquires Ion Chromatography Business From Transgenomic, Inc.

    September 10, 2015 — StoneCalibre, LLC announced that one of its affiliates, Edge BioSystems, Inc., has acquired the Ion Chromatography Business from Transgenomic, Inc. The Company will be renamed Concise Separations and is responsible for researching, developing, manufacturing, and marketing bulk resins and high performance liquid chromatography columns with applications in fields such as pharmaceuticals, foods, life sciences, environmental, and forensics.

  • Agilent Technologies to Acquire Seahorse Bioscience for $235M

    September 9, 2015 — Agilent will acquire Seahorse Bioscience, a provider of instruments and assay kits for measuring cell metabolism and bioenergetics. Seahorse Bioscience’s technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data. Seahorse’s FY15 revenue is estimated to be $49 million.

  • NantOmics Acquires OncoPlex Diagnostics

    September 10, 2015 — NantOmics, a molecular diagnostic company and a member of the NantWorks group of companies, has acquired the remaining shares of OncoPlex Diagnostics, an accredited clinical laboratory focused on testing tumor cell proteins using mass spectrometry analysis. OncoPlex provides comprehensive-profiling services of patients’ tumors intended to enable more informed and better treatment decisions.

  • Roche purchases nucleic acid purification technology from Lumora

    August 24, 2015 — Roche purchasd assets from Lumora for products associated with the Heat Elution1 technology for nucleic acid purification of multiple sample types including formalin-fixed paraffin-embedded (FFPE) tumor samples. The technology is environmentally friendly and can be applied to process a wide variety of sample types including whole blood, fecal matter, sputum, FFPE tissue and buccal swabs. Roche plans to explore integrating this technology into its sequencing workflow solution.

  • Illumina to Acquire GenoLogics

    August 4, 2015 — Illumina will acquire GenoLogics Life Sciences Software, a developer of laboratory information management systems (LIMS) for life sciences organizations. The acquisition strengthens Illumina’s portfolio of genetic analysis solutions. GenoLogics will become part of the Illumina Enterprise Informatics business.

  • OpGen to Acquire AdvanDx

    July 14, 2015 — OpGen, Inc. will acquire AdvanDx, Inc., a Woburn, Mass. developer of advanced molecular diagnostic products. The acquisition will be accounted for as a merger and will provides OpGen with a family of FDA approved and CE marked rapid molecular tests for use with the company’s Gene tests and bioinformatics for multi-drug resistant organisms.

  • Charles River Laboratories To Acquire Celsis International Ltd.

    July 9, 2015 — Charles River Laboratories International will acquire Celsis International Ltd. for $212 million in cash. Celsis provides rapid bacterial detection systems for quality control testing in the biopharmaceutical and consumer products industries, principally used for product-release testing to help ensure the safe manufacture of drugs and consumer products. The acquisition complements Charles River’s current offerings for rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing.

  • Eurofins will acquire major stake in Emory Genetics Lab

    June 29, 2015 — Eurofins Scientific has signed an agreement to acquire a 75% stake in Emory Genetics Laboratory (“EGL”) from Emory University’s School of Medicine for approximately US$ 40m in cash. EGL provides high-complexity molecular, biochemical and cytogenetic testing for rare and common genetic diseases and disorders. Founded in 1970, EGL employs around 100 staff at its laboratory in Atlanta, GA, and serves over 400 institutional clients across the US. It expects to generate revenues in excess of US$ 15m for 2015.

  • Ampersand Capital Partners Acquires Protein Technologies

    June 18, 2015 — Ampersand Capital Partners, a private equity firm with a focus on growth equity investments in the healthcare sector, will purchase Protein Technologies, Inc., a provider of peptide synthesis instrumentation. The investment will help Protein Technologies to meet increased demand as the peptide therapeutics market grows.

  • Thermo Fisher Scientific to Acquire Alfa Aesar for $405M

    June 25, 2015 — Thermo Fisher Scientific has agreed to acquire Alfa Aesar, a manufacturer of research chemicals and part of Johnson Matthey Plc, for approximately $405M in cash. Alfa Aesar makes chemicals used in drug discovery and development, as well as manufacturing, and in 2014 generated sales of approximately $125M.

  • GenDx Acquires Product Line from Quest/Celera

    June 19, 2015 — GenDx has acquired the AlleleSEQR product line from Quest subsidiary, Celera Diagnostics, and will manufacture and distribute the products for HLA Sequence-Based Typing. The products are used for matching donors and recipients prior to transplant, which reduces the risk of rejection. GenDx provides In Vitro Diagnostic (IVD) tests and services in the area of Sequencing-Based Typing (SBT) for transplantation.

  • Bio-Techne to Acquire Cliniqa Corporation

    June 5, 2015 — Bio-Techne Corporation, a provider of tools and bioactive reagents for the research and clinical diagnostic communities, has agreed to acquire 100% ownership of Cliniqa Corporation. Cliniqa specializes in the manufacturing and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market. Its controls and reagents are used in diagnostic tests for such pathologies as cardiac disease, diabetes, cancer, immunological disorders, therapeutic drug monitoring, urine analysis and toxicology.

  • OPKO Health Acquires Bio-Reference Laboratories for $1.47B

    June 4, 2015 — OPKO Health is buying Bio-Reference Laboratories for $1.47 billion for the company’s genetic sequencing technology and to harness Bio-Reference’s lab capabilities for drug development. Bio-Reference Laboratories is the third largest full service clinical laboratory in the U.S. and is known for as a pioneer in the areas of genomics and genetic sequencing. Opko intends to enhance Bio-Reference’s laboratory operations with its pipeline of diagnostic products. Also, Opko gets a national sales force to aid in the adoption the company’s test for aggressive prostate cancer.

  • Eurofins Buys Diatherix for $50 Million

    June 1, 2015 — Eurofins Scientific, a leader in bio-analytical testing and genomic services, has signed an agreement to acquire Diatherix Laboratories, Inc. for approximately US$ 50m, plus an earn-out. Diatherix is a provides molecular diagnostic testing services to hospitals and physicians using proprietary “Target Enriched Multiplex Polymerase Chain Reaction” technology for rapid detection of infectious diseases at high levels of sensitivity and specificity. Employing around 100, Diatherix expects to generate revenues of about US$ 40m in 2015.

  • Affymetrix Acquires Eureka Genomics for $15M

    May 14, 2015  Affymetrix has acquired Eureka Genomics Corp. for $15 million in an all cash transaction. Eureka Genomics is a developer of high throughput genotyping assays that use common next-generation sequencing (NGS) platforms for signal readout. These assays enable the detection of genetic markers for routine crop and animal agrigenomics testing. Affymetrix will launch the Eureka Genomics’ technologies as Eureka Genotyping Solution and Services for use in a wide range of routine animal and plant testing applications through an early access program.

  • Danaher to Buy Pall Corp for $13.8B, Split into Two

    May 13, 2015  Danaher Corp will buy air and water-filter maker Pall Corp in a $13.8 billion deal to tap into fast-growing demand from the biotechnology industry. Danaher would split into a science and technology company retaining the Danaher name and comprising Pall Corp as well as Danaher’s life sciences and diagnostics, dental, water quality and product identification businesses. The other company will make test and measurement products, retail fuel pumps, and telematics and automation products.

  • Agilent to Buy Cartagenia

    May 4, 2015  Agilent will acquire Cartagenia, a provider of software and services for clinical genetics and molecular pathology labs. Cartagenia provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Cartagenia’s solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe.

  • Sartorius Stedim Biotech Acquires BioOutsource

    4/17/2015  Sartorius Stedim Biotech, supplier for the biopharmaceutical industries, acquired the Scottish company BioOutsource Ltd. SSB provides fermentation, cell cultivation, filtration, purification, fluid management and lab technologies to the biopharmaceutical industry. BioOutsource provides contract testing services to biopharmaceutical clients to monitor the safety and quality of biologic drugs and vaccines, specializing in services for the biosimilar industry.

  • Rosetta to Acquire PersonalizeDx for $2M Plus Stock

    April 09, 2015  Rosetta Genomics Ltd., a developer and provider of microRNA-based and other molecular diagnostics, will acquire CynoGen, Inc. (dba PersonalizeDx) from Prelude Corporation. The acquisition is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party. PersonalizeDx is a molecular diagnostics and services company serving community-based pathologists, urologists, oncologists and other reference laboratories across the U.S. Through this transaction Rosetta Genomics will gain proprietary tests in prostate, bladder and lung cancer, and laboratory operations capabilities. The purchase price includes $2.0 million in cash, 500,000 shares of Rosetta Genomics Ltd.

  • Ambry Genetics Acquires Progeny Software

    April 1, 2015  Ambry Genetics announced the acquisition of Progeny Software. Ambry looks to integrate Progeny into its own laboratory information management system (LIMS) to simplify its clients’ workflow to make the genetic testing process more efficient.

  • Protea to Acquire VivoPharm for $11.2M

    March 31, 2015  Protea Biosciences Group, Inc. announced the purchase of vivoPharm Pty Ltd., for $11.2M including $5.4 million in cash and $5.7 million in new stock. Protea is a West Virginia based company developing direct molecular imaging. vivoPharm is a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models. The acquisition is subject to Protea raising at least $10 million in debt or equity financing. VivoPharm will operate as a business unit of Protea.

  • Quintiles, Quest Form Joint Venture

    March 31, 2015 Medical tests maker Quest Diagnostics Inc and contract research company Quintiles Transnational Holdings Inc said they were combining their clinical trial laboratory operations in a joint venture. Quintiles will own 60 percent of the joint venture, with Quest owning the rest. The combined revenue of the joint venture would have been about $575 million in 2014, the companies said.

  • FujiFilm to Acquire U.S. Cellular Dynamics for $307M

    March 30, 2015 FujiFilm Holdings Corporation will acquire Cellular Dynamics International, a manufacturer of human cells used in drug discovery and screenings. CDI’s cellular technology platform allows the company to develop fully-functioning human cells, including induced pluripotent stem cells (iPSCs), on an industrial scale. Fuji said the acquisition of CDI will allow the company to gain entry into the area of iPS cell-based drug discovery support services.

  • Esperite acquires InKaryo

    March 19, 2015 Swiss firm Esperite announced the acquisition of InKaryo, the US-based company specialized in cytogenetic analysis through next generation sequencing (NGS). The purchase price is USD260,000, and Esperite assume the obligations of a 2-year 6% USD 280,000 convertible bond due May 2015. It is expected that InKaryo’s eKaryotype test will provide higher quality at a fraction of the cost compared to existing methods, such as array-based comparative genomic hybridization or chromosomal microarray analysis.

  • Qiagen Acquires AdnaGen’s Circulating Tumor Cell (CTC) Enrichment Technology

    March 17, 2015 Qiagen acquired AdnaGen’s circulating tumor cell (CTC) enrichment technology to boost its capabilities in liquid biopsies. AdnaGen’s CTC method relies on magnetic particles in an antibody mixture that isolates and purifies mRNA for analysis using RT-PCR. Qiagen Manchester will co-develop a CTC-based companion diagnostic for Tokai Pharmaceutical.

  • Crown Bioscience, Inc. Buys PDX Unit From Molecular Response

    February 18, 2015 Crown Bioscience, a US-China preclinical CRO with a focus on oncology acquired the diagnostic oncology assets from Molecular Response of San Diego. Crown bought MRL’s PDX bank of several hundred established models for in vivo pharmacology services along with several other models under development. It also acquired access to 8,000 viable human tumors for the next two years. Also Crown will run MRL’s San Diego-based PDX service operations, which will become a Crown global center of excellence for Translational Oncology. The price was not disclosed.


  • Roche Acquires Signature Diagnostics

    February 9, 2015 Roche acquired Signature Diagnostics in a play to strengthen Roche’s cancer diagnostics effort. Signature has expertise in both biobanks and next-generation sequencing (NGS) assays, and will be integrated into Roche’s Sequencing Unit. Signature develops large blood plasma and tissue biobanks in multiple cancer including colorectal and lung cancers.

  • Abcam Buys Firefly for $28M

    January 21, 2015 Life science tools supplier Abcam will pay $28 million cash to acquire Firefly BioWorks, the developer of a multiplex assay platform for biomarker detection. The platform is based on microfabrication technology and has advanced its first product for detection of microRNAs (miRNAs).

  • DNAe Acquires nanoMR Inc. for $24M

    January 19, 2015 DNA Electronics Ltd., the inventors of semiconductor DNA sequencing technology and developers of point-of-need test for blood infections, has completed the acquisition of nanoMR Inc., an Albuquerque based developer of a system for rapid isolation of rare cells in the bloodstream. The acquisition ebnables the integration nanoMR’s unique immunomagnetic Pathogen Capture System with its own Genalysis® PCR and semiconductor-based DNA sequencing technology to create a complete blood-to-result solution.

  • Adaptive Biotechnologies Announces Acquisition of Sequenta, Inc

    January 7, 2015 Adaptive Biotechnologies Corporation, a pioneer in leveraging next generation sequencing to profile T-cell and B-cell receptors, has acquired Sequenta, Inc. This is expected to expedite and expand the use of novel immunosequencing products for researchers and clinicians to diagnose, treat, and monitor patients with cancer, autoimmune disorders, and infectious diseases. To date, Adaptive has primarily focused on developing tools and services for researchers, and Sequenta has focused on developing similar technology for use in monitoring of minimal residual disease, or MRD, for patients with blood cancers.

  • PerkinElmer Closes Acquisition of Perten Instruments

    December 16, 2014 PerkinElmer, Inc. announced the completion of its acquisition of Swedish firm, Perten Instruments Group AB in a $266 million deal. With annual revenues of about $65 million, Stockholm-based Perten Instruments is a supplier of advanced analytical instruments for quality control of food, grain, flour and feed. The acquisition is expected to significantly expand PerkinElmer’s presence in the rapidly growing area of food testing.

  • Roche Diagnostics Buys Tissue-Dissection Technology from AvanSci Bio

    December 10, 2014 Roche Diagnostics signed a deal with AvanSci Bio to buy all products associated with the high- performance microdissection of slide-mounted tissue sections. The system consists of instrumentation, software, and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis including real-time PCR, microarrays, and sequencing. AvanSci Bio’s technology includes the automated MilliSect instrument which reportedly enables a greater than 90% tumor enriched sample for molecular analysis.

  • LabCorp Announces Acquisition of Bode Technology

    December 05, 2014 Laboratory Corporation of America Holdings announced the completion of its acquisition of Bode Technology Group, Inc., from SolutionPoint International, Inc. As a wholly-owned subsidiary of LabCorp, Bode Technology and its division Chromosomal Labs will continue to provide specialized forensic DNA analysis, proprietary DNA collection products, and relationship testing to an international market. Under the new combined businesses, Cellmark Forensics and Bode Technology will provide DNA testing services to federal and state governments, law enforcement agencies, crime laboratories, disaster management organizations, and various consumer markets throughout the United States and around the world.

  • Noble Life Sciences Inc. Acquires Spring Valley Laboratories, Inc.

    December 3, 2014 Noble Life Sciences, a provider of preclinical drug development services, today announced the acquisition of Spring Valley Laboratories, a full service, GLP-compliant, preclinical contract research organization for the development of drugs, vaccines, and medical devices. The acquisition greatly expands Noble’s services to include GLP regulatory standards, studies in small and large animals, and testing capabilities for vaccines and medical devices. Combined with Noble’s recognized strength conducting studies directed at early-stage products, the acquisition of Spring Valley Laboratories extends the Company’s suite of offerings across the full continuum of preclinical studies from initial product discovery through regulation-compliant studies.

  • Roche Acquires Ariosa Diagnostics, Inc.

    December 2, 2014 Roche announced the acquisition of Ariosa Diagnostics, Inc., a privately-held company based in San Jose, California, USA. Ariosa is a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing service through their CLIA laboratory using cell-free DNA technology. Ariosa’s proprietary Prenatal Test is a blood test that is performed as early as 10 weeks into pregnancy, and is designed to assess the risk of Down syndrome and other genetic abnormalities.

  • Intertek Acquires ScanBi Diagnostics

    November 19, 2014 Intertek, a leading quality solutions provider to industries worldwide, has acquired ScanBi Diagnostics, a Swedish company providing global high-technology DNA and protein based accredited analyses and quality services for the agro-biotech, seed, agriculture, food, and feed industries. As part of the transaction, Intertek has also acquired 50 percent ownership of Lynx Diagnostics, a Canadian company providing testing of seed breeding and production materials for the North American market. Intertek ScanBi Diagnostics provides Nordic and international clients with expert GMO testing, genotyping, pathogen testing, species identification, hybrid breeding, allergen testing, quality assurance and more.

  • PDI Acquires RedPath Integrated Pathology

    November 3, 2014 PDI, Inc., a leading healthcare commercialization company, announced the acquisition of RedPath Integrated Pathology, a molecular diagnostics company helping physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG® platform. The acquisition immediately expands the oncology diagnostic product portfolio for PDI, Inc. subsidiary, Interpace Diagnostics, with a test currently generating approximately $10 million in revenue that is marketed for determining pancreatic cancer risk from pancreatic cysts, as well as tests in late-stage development for assessing cancer risk for Barrett’s esophagus and in the biliary tract. Terms of the deal include a $12M upfront payment, future milestone-based payments, future revenue-based payments, an $11M note.

  • LabCorp to Acquire Covance in $6.1B Deal

    November 3, 2014 Laboratory Corporation of America Holdings entered into a definitive agreement to acquire Covance Inc. for $105.12 per Covance share in cash and stock, or an equity value of approximately $6.1 billion and an enterprise value of approximately $5.6 billion. The combination will create the world’s leading healthcare diagnostics company, capitalizing on LabCorp’s industry leadership in medical testing and Covance’s leadership in contract research.

  • BD Acquires GenCell Biosystems

    October 13, 2014 — Becton, Dickinson and Company has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications. GenCell Biosystems acquisition provides BD entry into the Next Generation Sequencing market with a differentiated platform that will provide a base to further grow its genomics offerings. GenCell has created an automated platform that has the potential to address key unmet customer needs in library preparation for Next Generation Sequencing.

  • Immucor Acquires Sentilus

    October 1, 2014 – Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that it has acquired Sentilus, Inc., a privately-held company focused on developing a novel, inkjet-printed antibody microarray-based technology, Femtoarrays™. Sentilus has been developing Femtoarrays and the underlying technology for use in a variety of in vitro diagnostics areas, including transfusion diagnostics.

  • Horizon Discovery acquires Sage Labs for $48 million

    September 29, 2014 Horizon Discovery Group agreed to acquire Sage Labs in a deal designed to expand the buyer into the world’s leading gene editing company, with CRISPR/CAS9 platform technology and its own, fully integrated translational genomics platform. Horizon said Sage Labs will provide it with an expanded range of genetically engineered preclinical models through exclusive access to zinc finger nucleases (ZFN) for in vivo model generation and certain exclusive and nonexclusive CRISPR in vivo-related intellectual property to add to its extensive in vitro IP in CRISPR, ZFN and rAAV—the latter a worldwide exclusive to Horizon

    • Merck KGaA to Buy Sigma-Aldrich for $17B

      September 22, 2014 — Merck KGaA , a leading company in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $17.0 billion. Merck KGaA, Darmstadt, Germany, will acquire all of the outstanding shares of Sigma-Aldrich for $140 per share in cash, which represents a 37% premium to the latest closing price of $102.37 on September 19, 2014.

    • Veracyte, Inc. to Acquire Allegro Diagnostics, Accelerating Entry into Pulmonology Market

      Sept. 4, 2014 — Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, announced an agreement to acquire Allegro Diagnostics Corp. based in Maynard, Mass., for $21.0 million. Allegro is a privately held company focused on developing genomic tests to improve the preoperative diagnosis of lung cancer. Allegro’s lung cancer test is designed to help physicians determine which patients with lung nodules who have had a non-diagnostic bronchoscopy result are at low risk for cancer and can thus be safely monitored with CT scans rather than undergoing invasive procedures.

    • Analytik Jena AG to Acquire Bruker’s ICP-MS Business

      August 13, 2014 — Analytik Jena AG, a leading manufacturer of analytical measuring technology, life science instruments and optoelectronics, has signed an agreement to acquire the ICP-MS business of Bruker Corporation. Analytik Jena AG will acquire or license the entire product know-how belonging to Bruker’s ICP-MS product segment including patents and licensing rights, as well as global research, development and production capacities.

    • Thermo Fisher Scientific Completes Sale of Cole-Parmer to GTCR

      Aug. 18, 2014 — Thermo Fisher Scientific Inc. has completed the sale of its Cole-Parmer customer channel business to private equity firm GTCR LLC for approximately $480 million in cash. The business, which was part of the Laboratory Products and Services Segment, had approximately $230 million in revenues for full year 2013.

    • ReproCELL Acquires Reinnervate Limited And Bioserve, Inc.

      August 5, 2014 — Reprocell of Japan has acquired Reinnervate Ltd, one of the leading companies in the field of 3D cell culture. Reprocell, a pioneer in the field of induced pluripotent stem cell biology supplies iPSC-dervided Hepatocytes, Neurons and Cardiomyocytes as well as a range of media and reagents for stem cell culture.  Reprocell also announced the acquisition of BioServe Inc of MD, USA, a leading supplier of human tissues and other biological samples with one of the largest commercial biorepositories in the world.

    • Oxford Immunotec Limited Acquires Boulder Diagnostics For $7.9 Million

      Aug. 5, 2014 — Oxford Immunotec Global PLC, a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, has acquired Boulder Diagnostics Inc. Boulder Diagnostics is a private diagnostics company based in Boulder, Colorado that is developing immunology-based assays for rheumatology and infectious diseases.


    • Waters Acquires REIMS Technology, Strengthens Health Science Initiative

      July 22, 2014 — Waters Corporation announced the acquisition of Rapid Evaporative Ionization Mass Spectrometry (REIMS) technology from MediMass Ltd.  REIMS is the enabling technology for the “Intelligent Knife” or “iKnife,” a device in the conceptual stages of development that could potentially be used for real-time diagnostics in surgery.  Rohit Khanna, Vice-President, Worldwide Marketing and Informatics, Waters Division said “This technology acquisition along with our recent agreement with Prosolia, Inc. for the exclusive rights to Desorption Electrospray Ionization (DESI) technology in clinical applications are key components in our burgeoning Heath Sciences initiative. Both direct-from-sample ion source technologies are strategic discriminators as we look to grow the impact of mass spectrometry throughout the Health Sciences Continuum.”

    • Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting Firm

      Jul 16, 2014 — Illumina, Inc. today announced that it has acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics. Led by founder and CEO Mya Thomae, Myraqa focuses on regulatory strategy and application support, including PMAs, pre-submissions, IDEs, 510(k)s, de novo 510(k)s, and EU technical files. The acquisition will bolster Illumina’s in-house capabilities for clinical readiness and help prepare for its next growth phase in regulated markets.

    • NeoGenomics (NEO) Acquires Path Labs in $6M Deal

      July 8, 2014 — NeoGenomics announced that it has acquired Path Labs, LLC d/b/a Path Logic. Path Logic is a leading provider of specialized anatomic pathology services to Hospitals and physicians in Northern California. Path Logic provides high-quality Anatomic Pathology services with significant expertise in the sub-specialties of renal pathology, dermatopathology, women’s health and gastrointestinal and genitourinary pathology.

      For 2013, Path Logic reported revenue of approximately $10 million and employed approximately 65 people.  The transaction includes Path Logic’s main laboratory in West Sacramento, California as well as satellite facilities in Santa Ana and Fresno California. Path Logic will operate as a wholly-owned subsidiary of NeoGenomics to provide specialized anatomic pathology services for NeoGenomics’ clinical trials and pathology clients across the country.

    • StoneCalibre Acquires Nucleic Acid Purification Products Manufacturer Edge BioSystems, Inc.

      July 8, 2014 – StoneCalibre, a privately funded investment firm, announced today the completion of the acquisition of Edge Biosystems, Inc. headquartered in Gaithersburg, Maryland. Established in 1990, EdgeBio is a highly specialized manufacturer and distributor of sample preparation and clean-up products for use in DNA sequencing.

      EdgeBio’s consumable products are critical components in the DNA sequencing process allowing researchers to determine the exact genetic make-up of DNA for use in clinical and diagnostic labs, food testing, molecular medicine, ancestry studies and other applications. EdgeBio has built a solid reputation as a sequencing purification supplier of choice stemming from its consistent, high-quality product performance backed by its proprietary formulations.

      • Cancer Genetics to Buy Gentris for $4.75M

        Jun 23, 2014 Cancer Genetics, Inc., a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, announced the signing of a non-binding Letter of Intent (LOI) to acquire privately held Gentris Corporation, a leader in pharmacogenomics solutions, biomarker testing and biorepository services for approximately $4.75 million. “Gentris has world class expertise in pharmacogenomics that will be highly complementary to our existing oncology diagnostic business,” said Panna Sharma, Chief Executive Officer of Cancer Genetics. “We view this acquisition as part of our long-range strategic plan to deepen our capabilities in developing unique and individualized treatment insights in oncology.”

      • Bio-Techne to Buy ProteinSimple for $300M

        June 17, 2014 Techne Corporation announced that it has agreed to acquire ProteinSimple for $300 million in cash. ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. ProteinSimple tools have revolutionized the analysis of proteins and provide a level of reliability, ease of use and performance that improves overall productivity and consistency in lab results.

      • ViaLogy Acquiring Premaitha Health for ₤10.5M

        June 13, 2014 ViaLogy announced that it has conditionally acquired the entire issued share capital of Premaitha, which is a molecular diagnostic company, for ₤10.5 million. The net proceeds will be used to develop and commercialise the IONA® Test, a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha, and for general working capital purposes.

      • Wiley Buys SimBioSys

        June 12, 2014 John Wiley & Sons, Inc., a global provider of knowledge and knowledge-enabled solutions that improve outcomes in research, professional practice, and education, announced today that it has acquired SimBioSys Inc., a provider of scientific software tools that facilitate the drug discovery process. Terms were not disclosed. “The acquisition of SimBioSys accelerates the development of Wiley Science Solutions, our integrated suite of workflow tools for researchers,” said Dr. Mike Davis, Vice President and Managing Director, Research Innovations “SymBioSys has developed technology that enables the computer to learn organic chemistry. These tools enable chemists working in industry and academia to find new and better ways of synthesizing target compounds, saving them time and money.”

      • Roche acquires Genia Technologies

        June 2, 2014. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore technology. Under the terms of the agreement, Roche will pay Genia’s shareholders USD 125 million in cash. In addition to this payment from Roche, Genia’s shareholders may receive up to USD 225 million in contingent payments depending on the achievement of certain milestones. Genia’s proprietary technology is expected to reduce the price of sequencing while increasing speed and sensitivity. “The acquisition of Genia is a further step for Roche to introduce a potentially disruptive technology to the market,” said Roland Diggelmann, COO of Roche Diagnostics. “The addition of Genia’s single molecule semiconductor DNA sequencing platform using nanopore technology strengthens our next generation sequencing pipeline.”

      • Sequenom Sells Bioscience business to Agena Bioscience

        May 30, 2014. Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, announced that it has completed the sale of its Bioscience business to Agena Bioscience, a portfolio company of Telegraph Hill Partners. The terms of the agreement provide for a purchase price of $31.8 million. The acquired business will continue to manufacture and sell the MassARRAY(R) System, a proprietary mass spectrometry-based genetic analysis instrument and associated products and services that provide research and clinical investigators with economical high multiplexing, high volume results, and precise quantification in a well-established platform technology.

      • Novacyt to Combine with Lab21

        May 27, 2014. Novacyt, a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and all the other non-gynaecological cancers, announces its plans to combine in a stock-for-stock transaction with Lab21, the Cambridge, UK-based global specialist in personalised medicine and clinical diagnostics. On completing the transaction, Lab21 will become a 100% subsidiary of Novacyt, and the combined group will be rebranded.

      • QIAGEN Aquires BIOBASE

        May 21, 2014. QIAGEN announced the expansion of its industry-leading portfolio of bioinformatics solutions with additional content from BIOBASE, a provider of expertly curated biological databases, software and services. With access to HGMD, especially in clinical markets widely used biomedical data resource as well as to other unique content, QIAGEN expands its world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis – further strengthening its market-leading position in the analysis and interpretation of sequencing data.

      • Horizon Discovery Group to Acquire CombinatoRx

        May 15, 2014. Horizon Discovery Group plc, the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, announced it has agreed to acquire the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from Zalicus Inc. , a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, for £4.74m ($8.0m USD). The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon.